• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗凝剂量管理的质量评估:治疗范围内时间指标的比较评价

Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range.

作者信息

Schmitt L, Speckman J, Ansell J

机构信息

Departments of Medicine & Pharmacy, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA.

出版信息

J Thromb Thrombolysis. 2003 Jun;15(3):213-6. doi: 10.1023/B:THRO.0000011377.78585.63.

DOI:10.1023/B:THRO.0000011377.78585.63
PMID:14739631
Abstract

BACKGROUND

The results of clinical trials often hinge on the quality of oral anticoagulation management, yet the quality of such management is frequently not mentioned or measured. Time-in-therapeutic range (TTR) is one measure of quality of anticoagulation dose management, but various methodologies exist for measuring TTR.

OBJECTIVE

This study was initiated to compare three commonly used methodologies for measuring TTR to see how they compare within the same cohort of patients.

PATIENTS/METHODS: Three common methodologies of calculating time-in-therapeutic range were analyzed retrospectively in a cohort of patients over six two-month intervals. Additional analysis was performed for three and six-month intervals. The methodologies included fraction of INRs in range; cross-section of the files; and linear interpolation.

RESULTS

Fraction of the INRs in range and cross-section of the files methodologies gave similar results, while linear interpolation yielded significantly shorter time-in-range for the two-month, three-month, and six-month intervals measured. The advantages and disadvantages of each methodology are discussed.

CONCLUSIONS

The decision of which method to use should be based on clinic size, information desired, and clinic resources for ease of applying either of the methods in clinical practice. Each of these methodologies has their limitations and the question remains as to which method best reflects the quality of anticoagulation management. Regardless of these limitations, investigators are urged to employ at least one method of measuring the quality of oral anticoagulation management so as to better assess the validity of the clinical outcomes.

摘要

背景

临床试验结果常常取决于口服抗凝管理的质量,但这种管理的质量常常未被提及或衡量。治疗范围内时间(TTR)是抗凝剂量管理质量的一种衡量指标,但存在多种测量TTR的方法。

目的

开展本研究以比较三种常用的测量TTR的方法,看看它们在同一组患者中的比较情况。

患者/方法:回顾性分析了一组患者在六个为期两个月的时间段内计算治疗范围内时间的三种常用方法。还对三个月和六个月的时间段进行了额外分析。这些方法包括范围内国际标准化比值(INR)的比例;病历横断面;以及线性插值法。

结果

范围内INR的比例法和病历横断面法得出的结果相似,而线性插值法在测量的两个月、三个月和六个月时间段内得出的治疗范围内时间明显更短。讨论了每种方法的优缺点。

结论

使用哪种方法的决定应基于诊所规模、所需信息以及诊所资源,以便于在临床实践中应用这两种方法中的任何一种。这些方法都有其局限性,哪种方法最能反映抗凝管理质量的问题仍然存在。尽管有这些局限性,但仍敦促研究人员采用至少一种测量口服抗凝管理质量的方法,以便更好地评估临床结果的有效性。

相似文献

1
Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range.抗凝剂量管理的质量评估:治疗范围内时间指标的比较评价
J Thromb Thrombolysis. 2003 Jun;15(3):213-6. doi: 10.1023/B:THRO.0000011377.78585.63.
2
Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.基于国际标准化比值自我检测、在线远程监测与管理以及低剂量维生素K并考虑基因组因素的华法林管理评估:一项试点研究。
Pharmacotherapy. 2013 Nov;33(11):1136-46. doi: 10.1002/phar.1343. Epub 2013 Aug 22.
3
Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.新华法林患者口服抗凝控制的决定因素:来自临床实践研究数据库的数据分析。
Thromb Res. 2015 Aug;136(2):250-60. doi: 10.1016/j.thromres.2015.06.007. Epub 2015 Jun 9.
4
Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin.为忙碌的临床医生定义治疗范围内的时间:剂量变化频率是识别华法林抗凝效果欠佳患者的良好替代指标。
Thromb Res. 2014 Sep;134(3):584-6. doi: 10.1016/j.thromres.2014.06.024. Epub 2014 Jul 6.
5
Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar.基于药师的与基于医生的抗凝管理在卡塔尔的比较评估。
J Eval Clin Pract. 2016 Jun;22(3):433-8. doi: 10.1111/jep.12504. Epub 2016 Jan 14.
6
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).慢性非瓣膜性心房颤动患者在现实生活实践中口服抗凝管理的过程和质量描述性分析:抗凝管理国际研究(ISAM)
J Thromb Thrombolysis. 2007 Apr;23(2):83-91. doi: 10.1007/s11239-006-9022-7.
7
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.服用华法林时个体患者处于治疗范围内时间的替代计算方法:ROCKET AF试验结果
J Am Heart Assoc. 2015 Mar 3;4(3):e001349. doi: 10.1161/JAHA.114.001349.
8
Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.口服维生素K拮抗剂治疗的门诊管理:定义和衡量高质量管理
Expert Rev Cardiovasc Ther. 2008 Jan;6(1):57-70. doi: 10.1586/14779072.6.1.57.
9
Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing.在基层医疗中使用国际标准化比值即时检测进行高质量的口服抗凝治疗。
Dan Med J. 2015 Feb;62(2).
10
International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor.国际标准化比值变异性:抗凝质量的一种度量还是强大的死亡率预测指标?
J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2223-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.05.017. Epub 2015 Jul 29.

引用本文的文献

1
Fibrosis 4 Index Predicts Haemocompatibility-Related Adverse Events in Patients Using Left Ventricular Assist Devices.纤维化4指数可预测使用左心室辅助装置患者的血液相容性相关不良事件。
Eur J Cardiothorac Surg. 2025 Sep 2;67(9). doi: 10.1093/ejcts/ezaf291.
2
Association of serum potassium time in target range with cardiovascular outcomes in patients with HFpEF.射血分数保留的心力衰竭(HFpEF)患者血清钾在目标范围内的时间与心血管结局的关联
Open Heart. 2025 Aug 21;12(2):e003439. doi: 10.1136/openhrt-2025-003439.
3
Outcomes Associated with Time in Therapeutic Range for Patients Receiving Intravenous Unfractionated Heparin.接受静脉注射普通肝素治疗的患者,其治疗范围内的时间所关联的结果。
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251371003. doi: 10.1177/10760296251371003. Epub 2025 Aug 17.
4
Evaluation of the SAMe-TTR score to predict the quality of anticoagulation control in patients after mitral valve replacement.评估SAME-TTR评分对预测二尖瓣置换术后患者抗凝控制质量的作用。
Front Surg. 2025 Jun 9;12:1561690. doi: 10.3389/fsurg.2025.1561690. eCollection 2025.
5
The Application of Machine Learning in Warfarin Dose Precision for Diabetic Patients Treated with Statins: A Comparative Study.机器学习在接受他汀类药物治疗的糖尿病患者华法林剂量精准化中的应用:一项对比研究。
Cardiovasc Drugs Ther. 2025 May 31. doi: 10.1007/s10557-025-07690-5.
6
Time in target range for systolic blood pressure and stroke in people with and without diabetes: the Kailuan prospective cohort study.糖尿病患者和非糖尿病患者的收缩压目标范围内时间与中风:开滦前瞻性队列研究
Front Endocrinol (Lausanne). 2025 May 14;16:1537343. doi: 10.3389/fendo.2025.1537343. eCollection 2025.
7
Long-Term Systolic Blood Pressure Time in Target Range and Cardiovascular Disease in Individuals With Hypertension.高血压患者的长期收缩压处于目标范围内的时间与心血管疾病
JACC Adv. 2025 Apr 4:101702. doi: 10.1016/j.jacadv.2025.101702.
8
Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.2型糖尿病患者收缩压处于目标范围内的时间及估算肾小球滤过率斜率
Hypertens Res. 2025 May;48(5):1787-1798. doi: 10.1038/s41440-025-02173-4. Epub 2025 Mar 10.
9
Systolic Blood Pressure Time in Target Range and Cardiovascular Disease and Premature Death.收缩压处于目标范围内的时间与心血管疾病及过早死亡
JACC Asia. 2024 Oct 29;4(12):987-996. doi: 10.1016/j.jacasi.2024.09.002. eCollection 2024 Dec.
10
Traditional versus intensive blood glucose control: long-term target range duration and cardiovascular disease risk and all-cause mortality - a real-world cohort study.传统血糖控制与强化血糖控制:长期目标范围持续时间、心血管疾病风险及全因死亡率——一项真实世界队列研究
Front Endocrinol (Lausanne). 2024 Dec 10;15:1449925. doi: 10.3389/fendo.2024.1449925. eCollection 2024.

本文引用的文献

1
Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.比较短效醋硝香豆素和长效苯丙香豆素的口服抗凝治疗的疗效质量控制
Br J Haematol. 2002 Jun;117(4):940-6. doi: 10.1046/j.1365-2141.2002.03493.x.
2
Consensus needed for evaluating safe and adequate anticoagulant control.评估安全且充分的抗凝控制需要达成共识。
Arch Intern Med. 2001 Jun 25;161(12):1558. doi: 10.1001/archinte.161.12.1558.
3
Managing oral anticoagulant therapy.管理口服抗凝治疗。
Chest. 2001 Jan;119(1 Suppl):22S-38S. doi: 10.1378/chest.119.1_suppl.22s.
4
Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.抗凝管理作为不良事件的一个风险因素:改进的依据。
J Thromb Thrombolysis. 1998 Jan;5 Suppl 1(3):13-18. doi: 10.1023/a:1013276601930.
5
Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management.检测频率与抗凝治疗结果之间的关系:一项文献综述及评论,对患者自我管理随机试验的设计具有启示意义。
J Thromb Thrombolysis. 2000 Apr;9(3):283-92. doi: 10.1023/a:1018778914477.
6
Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists.
Thromb Haemost. 1999 Oct;82(4):1260-3.
7
Clinical coagulation laboratory and oral anticoagulant therapy treatment. Instrumentation and methodology.临床凝血实验室与口服抗凝治疗。仪器与方法。
Thromb Haemost. 1995 Jul;74(1):511-4.
8
A method to determine the optimal intensity of oral anticoagulant therapy.一种确定口服抗凝治疗最佳强度的方法。
Thromb Haemost. 1993 Mar 1;69(3):236-9.
9
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.口服抗凝治疗中的出血并发症。危险因素分析。
Arch Intern Med. 1993 Jul 12;153(13):1557-62. doi: 10.1001/archinte.153.13.1557.
10
A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol).口服抗凝治疗质量的比较研究(华法林与醋硝香豆素)
Thromb Haemost. 1994 Feb;71(2):188-91.